Non-Alcoholic Steatohepatitis Biomarkers Market Research Report - Global Forecast till 2027

Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Report: Information by Disease Outlook, Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Others), End User (Pharmaceutical Companies and CROs, Others) and Region­­ - Forecast till 2027

ID: MRFR/HC/6512-CR | June 2019 | Region: Global | 111 pages

Please note that the assessment period of report has been updated from 2018-2024 to 2020-2027. Cordially fill the sample form for updated data.

Market Overview


TheGlobal Non-Alcoholic Steatohepatitis Biomarkers Market is Expected to Register a CAGR of 20.92% and is Anticipated to Reach USD 1,960.4 million by 2024. Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD), which is characterized by liver inflammation and damage caused by a buildup of fat in the liver. Currently, there is no single test approved for diagnosing non-alcoholic steatohepatitis.


The market of non-alcoholic steatohepatitis biomarkers is expected to grow very well in the forecast period with around 30.3% CAGR. The market was valued to be USD 200.4 million in 2016, which is expected to reach more than 2100.6 million by 2027. The rapid growth of this market is expected to happen due to the rising NASH prevalence, raising awareness all around the world, and demand for non-invasive tests. Non-alcoholic steatohepatitis biomarkers is a disease type that is marked by liver inflammation.


The government funds are increasing for the non-alcoholic steatohepatitis biomarkers research, innovations, technology advancement, and others. It can affect the market significantly to increase the growth. Apart from governments, there are many non-profit organizations around the world that are supporting the non-alcoholic steatohepatitis biomarkers market by spreading awareness and making investments. There are many initiatives that are under the process that can create growth opportunities for this market in the forecast period. 


Covid 19 Analysis


COVID 19 affected the global economy by temporarily shutting down many industries. Among all of them, the non-alcoholic steatohepatitis biomarkers market also suffered a lot during the time of the pandemic. The production chain, manufacturing, everything got disrupted during the lockdown. Although most of the regions have resumed successfully, there are some places where the companies are still preparing. The demand for diagnostic tools that are non-invasive has increased a lot during the period. So, the economic condition of the market is expected to grow very fast.


 


Market Dynamics



  • Drivers


The major driving factors of the non-alcoholic steatohepatitis biomarkers market are the increasing demand for diagnostic tools that are not invasive and the rising awareness of patients. The cost of liver biopsy is very high, not very much accepted by the patients, and invasiveness makes the invasive techniques less adopted by the patients and healthcare professionals. Due to all these disadvantages of invasive techniques, the non-alcoholic steatohepatitis biomarkers market is projected to grow a lot.


While some of the techniques like magnetic resonance imaging, computed tomography, and ultrasound scanning can help to get accurate NAFLD results. They fail to detect liver fibrosis in most instances. So, the demand for noninvasive diagnostic tools gets even higher with the only accurate detection. In the upcoming years, the non-alcoholic steatohepatitis biomarkers market is expected to grow very well due to these factors.



  • Opportunities


The increasing number of initiatives in the non-alcoholic steatohepatitis biomarkers market is expected to develop the growth of this market. For example, the NASH Education Program is one of the very good initiatives that is started by the company named GENFIT in the year 2016 that helps to spread awareness to people about NASH. These types of initiatives are expected to open many opportunities for the non-alcoholic steatohepatitis biomarkers market.



  • Restraints


Although the non-alcoholic steatohepatitis biomarkers market is expected to witness high growth in the forecast period, there are some factors that can slow it down. One of the major factors among them is the restriction of the US FDA for the biomarkers is expected to create hurdles for the market growth. Apart from that, the high cost of the tools is also hindering the growth of this market. 



  • Challenges


Some of the common challenges that the non-alcoholic steatohepatitis biomarkers market need to overcome are the government policies. Also, the strict regulations of the US FDA make it hard for the non-alcoholic steatohepatitis biomarkers market to grow very much. However, the latest research and innovations in the upcoming years are expected to overcome all the challenges. After the COVID 19, most of the companies have come out of the bad situation and resumed their manufacturing to provide the high demand. 



  • Cumulative Growth Analysis


The growth in the market of non-alcoholic steatohepatitis biomarkers is expected to rise more than USD 200.4 million in the forecast period. With a high CAGR of 30.3%, the market is expected to have high growth during the forecast period. With the rising demand for non-surgical procedures, absence of NASH treatment test, spreading awareness of government and nonprofit organizations is expected to propel the growth of the non-alcoholic steatohepatitis biomarkers market in the forecast period.


Value Chain Analysis


As NASH is an increasing disease in almost all regions, very high funding and investments are contributed by different organizations and governments for advancement. Companies around the world are now keeping their ears and eyes open to have an effective cure. While strict regulations and others are holding back the growth of the non-alcoholic steatohepatitis biomarkers market, it is expected that the market will grow with the spreading awareness and demand of the biomarkers among patients and healthcare professionals.


Segment Overview


The global market of non-alcoholic steatohepatitis biomarkers is segmented into end-user and type. Here are the sub-segments of these segments are given below.


By Type,



  • Hepatic Fibrosis Biomarkers

  • Serum Biomarkers

  • Oxidative Stress Biomarkers

  • Apoptosis Biomarkers

  • Others


Among all of these sub-segments, the serum biomarkers hold the largest non-alcoholic steatohepatitis biomarkers market share by type. It is mostly due to the associated benefits like efficient outcomes, distinguishing ability from simple steatosis and NASH, and others. It is the most common tool of diagnosis that is used to detect NASH. Some of the other product introductions like tumor & ghrelin necrosis factor-alpha, leptin, apolipoprotein B, free fatty acids, adiponectin, apolipoprotein A1, and others are provided better services than the traditional ones.


 


By End-User,


 



  • Research Institutes and Academics

  • Diagnostic Centres

  • Pharmaceutical Companies and CROs

  • Hospitals and Clinics

  • Others


The largest share of the non-alcoholic steatohepatitis biomarkers market is occupied by the pharmaceutical industry. The growth of this segment is expected to rise more because of the demand for monitoring tools, non-invasive NASH diagnostic, and others.


Regional Analysis


There are mainly 5 regions that are known for having very good non-alcoholic steatohepatitis biomarkers market growth such as Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. Among them, Asia Pacific is expected to have the best growth during the forecast period based on the R & D rise in Japan and China, increased awareness, new technologies, and others.


Competitive Landscape


There are many companies available in the market that are leading the non-alcoholic steatohepatitis biomarkers market. Also, many new players are entering the market with improved strategies and innovations. Some of the major players in this market areOne Way Liver, BioPredictive, Cisbio, Celerion, Enterome, Echosens, GENFIT, NGM Biopharmaceuticals, and many others.


List of Key Companies:



  • Perspectum Diagnostics Ltd.

  • Shenzhen New Industries Biomedical Engineering Co Ltd

  • One Way Liver SL

  • BioPredictive

  • Cisbio

  • Celerion

  • Enterome

  • Echosens

  • GENFIT

  • NGM Biopharmaceuticals

  • Laboratory Corporation of America Holdings

  • Pacific Biomarkers

  • Quest Diagnostics Ltd

  • Prometheus Laboratories Inc

  • Regulus Therapeutics Inc.

  • Xeptagen SpA

  • Boehringer Ingelheim GmbH Inc.

  • Bristol-Myers Squibb

  • AstraZeneca

  • Pfizer Inc.


 


Recent Developments



  • Quest Diagnostics made a partnership with Houston Healthcare to improve the delivery services of the laboratory in 2018. They are expected to boost their position with this partnership in the upcoming years

  • Siemens Healthineers in 2018 November, announced the approval of the RLF test breakthrough from the FDA. It is intended to help the patients get more effective and time-efficient diagnoses to get better treatment from the life-threatening disease. 

  • Prometheus launched the FIBROSpect NASH test in 2017 October to help the NASH patients get better services based on liver fibrosis severity. The company is expecting to catch up to a higher position in the market with the introduction of this test.


Report Overview


This report contains in-depth information about both the market growth of nonalcoholic steatohepatitis biomarkers and regional growth analysis. Apart from that, there are some sections like challenges, restraints, drivers, growth analysis, segmentation, competitive landscape, and many more. All the information that is provided in this report is taken from different primary and secondary sources to provide the best growth projection in the forecast period.


Report Detail



  • Historic Period: 2018-2021

  • Base Year: 2021

  • Forecast Period: 2021-2027


By Geographically:



  • Asia Pacific

  • Europe

  • North America

  • Latin America

  • Middle East & Africa


 



Frequently Asked Questions (FAQ) :


Among all the different segments, Serum biomarkers hold the largest market share of non-alcoholic steatohepatitis biomarkers with more than 32.3% due to major benefits like understanding NASH from simple steatosis that makes the outcomes efficient. With these benefits, the need of doing liver biopsy has reduced and increased the growth of this market.

Major key players of the non-alcoholic steatohepatitis biomarkers market are AstraZeneca, GENFIT, Bristol-Myers Squibb, Boehringer Ingelheim GmbH Inc., Gilead, Novartis, Pfizer Inc., Quest Diagnostics, Siemens Healthineers, Xeptagen SPA, Prometheus Laboratories Inc, Laboratory Corporation of America Holdings, One way Liver SL, NGM Biopharmaceuticals, Echosens, BioPredictive, Cisbio, Celerion, Enterome, Shenzhen New Industries Biomedical Engineering Co. Ltd., and others. Many new companies are entering the non-alcoholic steatohepatitis biomarkers market with new strategies and products.

The global non-alcoholic steatohepatitis biomarkers market is expected to grow more than 2.20 billion in the forecast period. The CAGR is projected to be around 30.4% with the increasing chronic liver condition cases.

1 Executive Summary

1.1 Market Attractiveness Analysis 16

2 Market Introduction

2.1 Definition 18

2.2 Scope Of The Study 18

2.3 Assumptions 18

2.4 Market Structure 18

3 Research Methodology

3.1 Research Process 19

3.2 Primary Research 20

3.3 Secondary Research 21

3.4 Market Size Estimation 22

3.5 Forecast Model 22

4 Market Dynamics

4.1 Overview 23

4.2 Drivers 24

4.2.1 Increasing Prevalence Of Diabetes And Obesity 24

4.2.2 Growing Demand For Non-Invasive Tests 24

4.2.3 Rising Public And Private Sector Initiatives To Increase Awareness About NASH 24

4.3 Restraints 25

4.3.1 Stringent Regulatory Scenario 25

4.4 Opportunities 25

4.4.1 Growing Mergers And Acquisitions To Develop Novel Biomarkers 25

5 Market Factor Analysis

5.1 Value Chain Analysis 26

5.1.1 R&D And Designing 26

5.1.2 Manufacturing 26

5.1.3 Distribution & Sales 26

5.1.4 Post-Sales Review 27

5.2 Porter’s Five Forces Model 27

5.2.1 Bargaining Power Of Suppliers 27

5.2.2 Bargaining Power Of Buyers 28

5.2.3 Threat Of New Entrants 28

5.2.4 Threat Of Substitutes 28

5.2.5 Intensity Of Rivalry 28

5.3 Pipeline Analysis 28

5.3.1 Overview 28

5.3.2 Recent Developments In Product Pipeline 29

5.4 Regulatory Landscape 29

5.5 Non-Alcoholic Steatohepatitis Biomarkers: Disease Cause Outlook 30

5.5.1 Overview 30

5.5.2 Obesity 30

5.5.3 Type 2 Diabetes 30

5.5.4 Hyperlipidemia 31

5.5.5 Hypertension 31

5.5.6 Metabolic Syndrome (MetS) 31

6 Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

6.1 Overview 32

6.2 Serum Biomarkers 34

6.3 Hepatic Fibrosis Biomarkers 35

6.4 Apoptosis Biomarkers 37

6.5 Oxidative Stress Biomarkers 38

6.6 Others 38

7 Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

7.1 Overview 39

7.2 Pharmaceutical Companies And CROs 41

7.3 Research Institutes And Academic Centers 42

7.4 Diagnostic Centers 43

7.5 Hospitals & Clinics 44

8 Global Non-Alcoholic Steatohepatitis Biomarkers Market, By Region

8.1 Overview 45

8.2 Americas 47

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.2.1 North America 49

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.2.1.1 US 51

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.2.1.2 Canada 52

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.2.2 Latin America 53

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3 Europe 55

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1 Western Europe 58

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.1 UK 60

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.2 Germany 61

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.3 France 62

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.4 Italy 63

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.5 Spain 64

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.1.6 Rest Of Western Europe 65

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.3.2 Eastern Europe 66

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4 Asia-Pacific 67

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.1 Japan 69

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.2 China 70

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.3 India 71

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.4 Australia 72

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.5 South Korea 73

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.4.6 Rest Of Asia-Pacific 74

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.5 Middle East & Africa 76

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.5.1 Middle East 78

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

8.5.2 Africa 79

Non-Alcoholic Steatohepatitis Biomarkers Market, By Type

Non-Alcoholic Steatohepatitis Biomarkers Market, By End User

9 Competitive Landscape

9.1 Overview 81

9.2 Key Development Analysis 82

10 Company Profiles

10.1 BioPredictive 83

10.1.1 Company Overview 83

10.1.2 Financial Overview 83

10.1.3 Products/Services Offered 83

10.1.4 Key Developments 83

10.1.5 SWOT Analysis 83

10.1.6 Key Strategies 84

10.2 Celerion 85

10.2.1 Company Overview 85

10.2.2 Financial Overview 85

10.2.3 Products/Services Offered 85

10.2.4 Key Developments 85

10.2.5 SWOT Analysis 85

10.2.6 Key Strategies 85

10.3 Cisbio 86

10.3.1 Company Overview 86

10.3.2 Financial Overview 86

10.3.3 Products/Services Offered 87

10.3.4 Key Developments 87

10.3.5 SWOT Analysis 88

10.3.6 Key Strategies 88

10.4 Echosens 89

10.4.1 Company Overview 89

10.4.2 Financial Overview 89

10.4.3 Products/Services Offered 89

10.4.4 Key Developments 89

10.4.5 SWOT Analysis 90

10.4.6 Key Strategies 90

10.5 Enterome 91

10.5.1 Company Overview 91

10.5.2 Financial Overview 91

10.5.3 Products/Services Offered 91

10.5.4 Key Developments 91

10.5.5 SWOT Analysis 91

10.5.6 Key Strategies 91

10.6 GENFIT 92

10.6.1 Company Overview 92

10.6.2 Financial Overview 92

10.6.3 Products/Services Offered 92

10.6.4 Key Developments 92

10.6.5 SWOT Analysis 93

10.6.6 Key Strategies 93

10.7 Laboratory Corporation Of America Holdings 94

10.7.1 Company Overview 94

10.7.2 Financial Overview 94

10.7.3 Products/Services Offered 95

10.7.4 Key Developments 95

10.7.5 SWOT Analysis 95

10.7.6 Key Strategies 95

10.8 NGM Biopharmaceuticals 96

10.8.1 Company Overview 96

10.8.2 Financial Overview 96

10.8.3 Products/Services Offered 96

10.8.4 Key Developments 96

10.8.5 SWOT Analysis 96

10.8.6 Key Strategies 96

10.9 One Way Liver, SL 97

10.9.1 Company Overview 97

10.9.2 Financial Overview 97

10.9.3 Products/Services Offered 97

10.9.4 Key Developments 97

10.9.5 SWOT Analysis 97

10.9.6 Key Strategies 97

10.10 Pacific Biomarkers 98

10.10.1 Company Overview 98

10.10.2 Financial Overview 98

10.10.3 Products/Services Offered 98

10.10.4 Key Developments 98

10.10.5 SWOT Analysis 99

10.10.6 Key Strategies 99

10.11 Prometheus Laboratories Inc. 100

10.11.1 Company Overview 100

10.11.2 Financial Overview 100

10.11.3 Products/Services Offered 101

10.11.4 Key Developments 101

10.11.5 SWOT Analysis 101

10.11.6 Key Strategies 101

10.12 Perspectrum Diagnostics Ltd 102

10.12.1 Company Overview 102

10.12.2 Financial Overview 102

10.12.3 Products/Services Offered 102

10.12.4 Key Developments 102

10.12.5 SWOT Analysis 102

10.12.6 Key Strategies 102

10.13 Quest Diagnostics 103

10.13.1 Company Overview 103

10.13.2 Financial Overview 103

10.13.3 Products/Services Offered 104

10.13.4 Key Developments 104

10.13.5 SWOT Analysis 104

10.13.6 Key Strategies 104

10.14 Regulus Therapeutics, Inc. 105

10.14.1 Company Overview 105

10.14.2 Financial Overview 105

10.14.3 Products/Services Offered 105

10.14.4 Key Developments 105

10.14.5 SWOT Analysis 106

10.14.6 Key Strategies 106

10.15 Siemens Healthineers 107

10.15.1 Company Overview 107

10.15.2 Financial Overview 107

10.15.3 Products/Services Offered 108

10.15.4 Key Developments 108

10.15.5 SWOT Analysis 108

10.15.6 Key Strategies 108

10.16 Shenzhen New Industries Biomedical Engineering Co., Ltd 109

10.16.1 Company Overview 109

10.16.2 Financial Overview 109

10.16.3 Products/Services Offered 109

10.16.4 Key Developments 109

10.16.5 SWOT Analysis 109

10.16.6 Key Strategies 109

10.17 Xeptagen SpA 110

10.17.1 Company Overview 110

10.17.2 Financial Overview 110

10.17.3 Products/Services Offered 110

10.17.4 Key Developments 110

10.17.5 SWOT Analysis 110

10.17.6 Key Strategies 110

11 Appendix

11.1 References 111

11.2 Related Reports 111

12 List Of Tables

TABLE 1 NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET: PIPELINE ANALYSIS 28

TABLE 2 NAFLD ASSOCIATED DISEASE CONDITIONS 30

TABLE 3 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 33

TABLE 4 GLOBAL NASH BIOMARKERS MARKET FOR SERUM BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 5 CLASSIFICATION OF LIVER FIBROSIS BIOMARKERS 35

TABLE 6 GLOBAL NASH BIOMARKERS MARKET FOR HEPATIC FIBROSIS BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 36

TABLE 7 GLOBAL NASH BIOMARKERS MARKET FOR APOPTOSIS BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 8 GLOBAL NASH BIOMARKERS MARKET FOR OXIDATIVE STRESS BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 9 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 40

TABLE 10 GLOBAL NASH BIOMARKERS MARKET FOR PHARMACEUTICAL COMPANIES AND CRO, BY REGION, 2020–2027 (USD MILLION) 41

TABLE 11 GLOBAL NASH BIOMARKERS MARKET FOR RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY REGION,

2020–2027 (USD MILLION) 42

TABLE 12 GLOBAL NASH BIOMARKERS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 13 GLOBAL NASH BIOMARKERS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 14 GLOBAL NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 15 AMERICAS: NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 48

TABLE 16 AMERICAS: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 48

TABLE 17 AMERICAS: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 49

TABLE 18 NORTH AMERICA: NASH BIOMARKERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 50

TABLE 19 NORTH AMERICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 50

TABLE 20 NORTH AMERICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 51

TABLE 21 US: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 51

TABLE 22 US: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 52

TABLE 23 CANADA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 24 CANADA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 53

TABLE 25 LATIN AMERICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 26 LATIN AMERICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 54

TABLE 27 EUROPE: NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 56

TABLE 28 EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 29 EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 57

TABLE 30 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 58

TABLE 31 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 32 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 59

TABLE 33 UK: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 34 UK: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 60

TABLE 35 GERMANY: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 36 GERMANY: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 61

TABLE 37 FRANCE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 38 FRANCE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 62

TABLE 39 ITALY: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 40 ITALY: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 41 SPAIN: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 42 SPAIN: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 64

TABLE 43 REST OF WESTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 44 REST OF WESTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 65

TABLE 45 EASTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 46 EASTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 66

TABLE 47 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 68

TABLE 48 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 49 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 69

TABLE 50 JAPAN: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 51 JAPAN: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 70

TABLE 52 CHINA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 53 CHINA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 71

TABLE 54 INDIA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 55 INDIA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 72

TABLE 56 AUSTRALIA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 57 AUSTRALIA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 73

TABLE 58 SOUTH KOREA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 59 SOUTH KOREA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 74

TABLE 60 REST OF ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 61 REST OF ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 75

TABLE 62 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY REGION, 2020–2027 (USD MILLION) 77

TABLE 63 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 64 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 78

TABLE 65 MIDDLE EAST: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 66 MIDDLE EAST: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 79

TABLE 67 AFRICA: NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 68 AFRICA: NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 80

TABLE 69 TOP MANUFACTURERS IN THE GLOBAL NASH BIOMARKERS MARKET 81

13 List Of Figures

FIGURE 1 MARKET SYNOPSIS 15

FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL NASH BIOMARKERS MARKET 16

FIGURE 3 GLOBAL NASH BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%) 16

FIGURE 4 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 17

FIGURE 5 GLOBAL NASH BIOMARKERS MARKET SHARE, BY END USER, 2020 (%) 17

FIGURE 6 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2020–2027 (USD MILLION) 17

FIGURE 7 GLOBAL NASH BIOMARKERS MARKET: MARKET STRUCTURE 18

FIGURE 8 RESEARCH PROCESS OF MRFR 19

FIGURE 9 TOP-DOWN & BOTTOM-UP APPROACH 22

FIGURE 10 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 23

FIGURE 11 VALUE CHAIN: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 26

FIGURE 12 PORTER’S FIVE FORCES ANALYSIS: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 27

FIGURE 13 GLOBAL NASH BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%) 32

FIGURE 14 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2020 AND 2027 (USD MILLION) 33

FIGURE 15 GLOBAL NASH BIOMARKERS MARKET SHARE, BY END USER, 2020 (%) 39

FIGURE 16 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 40

FIGURE 17 GLOBAL NASH BIOMARKERS MARKET SHARE, BY REGION, 2020 (%) 45

FIGURE 18 GLOBAL NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 46

FIGURE 19 AMERICAS: NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 47

FIGURE 20 NORTH AMERICA: NASH BIOMARKERS MARKET, BY COUNTRY, 2020 AND 2027 49

FIGURE 21 EUROPE: NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 55

FIGURE 22 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY COUNTRY, 2020 AND 2027 58

FIGURE 23 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY COUNTRY, 2020 AND 2027 67

FIGURE 24 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY REGION, 2020 AND 2027 76

FIGURE 25 GLOBAL NASH BIOMARKERS MARKET: COMPETITIVE LANDSCAPE 82



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.